secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001326190-24-000016
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune reports Q1 2024 net loss $24.4M; cash $182.1M; pemvidutide milestones on track
--------------------------------------------------------------------------------

- Net loss $24.4M ($0.34/share) vs $20.1M ($0.40) in Q1 2023; R&D expense $21.5M on pemvidutide and HepTcell winddown.
- Cash, equivalents & short-term investments $182.1M as of March 31, 2024.
- Phase 2b MASH trial (IMPACT) enrollment ongoing; top-line results expected Q1 2025.
- End-of-Phase 2 FDA meeting for pemvidutide obesity program expected late Q3 2024.
- MOMENTUM Phase 2 data showed 74.5% weight loss from fat, 25.5% from lean mass; visceral fat preferentially reduced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619024000016/0001326190-24-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619024000016/alt-20240509x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-24-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer